<DOC>
	<DOC>NCT00751361</DOC>
	<brief_summary>Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.</brief_summary>
	<brief_title>Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>50 to 85 years old diagnosis of AMD in both eyes must have dry AMD in the study eye Study eyes with bestcorrected ETDRSvisual acuity of 0.10.8 peripheral veins allowing vascular access to establish the extracorporal circuit. other retinal or choroidal disorders than AMD optic nerve disease, glaucoma conditions that limit the view of the fundus acute bleeding in any eye General exclusion criteria for the treatment of Rheopheresis: anaemia haemorrhagic diathesis or coagulopathy diabetes serious acute or chronic kidney or liver failure hypotension systolic &lt; 100 mmHg chronic viral infection (HIV, hepatitis B, C) epilepsia, psychosis or dementia a malignant disease or any other condition with life expectancy &lt; 12 months known history of alcohol or drug abuse and long term serious nicotine abuse</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Rheopheresis</keyword>
	<keyword>Dry Age Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>apheresis</keyword>
	<keyword>microcirculation</keyword>
</DOC>